Data Safety Monitoring Board Says NeoStem To Continue PreSERVE AMI Phase 2 Trial

(RTTNews) - NeoStem, Inc.(NBS) said Tuesday, on September 13, the Data Safety Monitoring Board recommended continuing the PreSERVE AMI Phase 2 clinical trial of AMR-001, following a third interim data and safety review,. The trial is randomized, placebo controlled, double-blind study designed to treat 160 patients, and AMR-001 is being evaluated for the preservation of heart function after a severe heart attack.

"We are very excited and encouraged by the enrollment progress of the PreSERVE Phase 2 clinical trial," said Robin Smith, Chairman and CEO. He added, "We are on track to complete patient enrollment for this trial in 2013 with data read out 6-8 months after the last patient is infused."